Mobile
health or mHealth is amongst the greatest advanced developments within
the healthcare industry which have proven incredible growth over the
last couple of years. This phenomenon is noticed because of the growth
in personal health devices, that can be easily worn or can be used by
having a smart phone or can be used in a tablet. Mobile Health means the
usage of mobile communications, such as for example personal digital
assistant, mobile phones, laptops and so on, for health and information
services. Based on the Cutting Edge Information's white paper release
2015, the value of mHealth within the pharmaceutical sector will keep
growing.
Although
figures don't always show the overall facts, certain figures mentioned
within the white paper are very informative. During the 1st quarter in
2014 the overall mHealth applications on the iOS and the Android
platforms leaped over 100,000 and keeps growing. Even more informative
is that in the past thirty months 5,000 among those applications gained
revenues over $1 million. Mobile strategies this time account for 14% of
marketing blends of teams which were surveyed. Some other sources
apparently support these results. According to the predictions of Mobile
Health Market News, clinical mHealth spending is going to rise $2.5
billion during 2011 to 2016. As per mHealthWatch predictions, the
mHealth industry by 2017 will reach $26 billion.
In
the industry where information is essential and suggestions by external
partners are so crucial, the appeal is obviously clear. Even, the paper
alerts pharma not to fully depend on mobile technologies to get desired
outcomes. With the help of these devices to enhance medical education
along with patient adherence, businesses can better place themselves to
take advantage of mHealth in the future. Nowadays, a lot more consumers
rely on the internet, usually through their smartphones, than in the
past to get medical information. Whereas text message campaigns don't
need smart phones, but to access the internet it does requires. The
global penetration for mobile broadband is 32% just the double what it
had been in the year 2011. In Europe, it is 64% which is the highest
penetration rate, when compared to North & South America together it
is just 59%. The broadband speed also must be considered, as it can
vary across geographic areas because it differs around geographic
locations.
While smartphones along with tablets are increasing all over the world, companies have turned to mHealth development services
in order to improve interaction with the patients. Uses to cover
anything from text messages to the remind patients for having medicines
to even more interactive systems which could coordinate, for instance, a
glucose meter by using a mobile app for the diabetes patients.
There
could be unwillingness from Big Pharma getting involved in new
technologies, particularly when they're not sure with the Food and Drug
Administration (FDA)'s position. The FDA has reviewed mHealth
technologies and also the level that it may need to regulate them. What
sort of mobile apps could be subject to regulatory oversight had been
specified in the Safety and Innovation Act of 2012, whereas final
guidance given during September 2013 highlighted the FDA will focus its
concern upon medical mobile devices. As a whole, the FDA promises to
work out its regulatory oversight upon mobile applications which either
function in connection using a separate medical device otherwise change a
current mobile platform, for instance tablet, Android, an iPhone and
more, to the regulated medical device, reports the paper. Actually, in
cases where a mobile app has got the potential to have an effect on
patient safety for the better or even for worse, then the FDA wants to
examine it. Some other mobile initiatives would be examined on the case
by case basis.
Although
mHealth is really an approach for pharma companies in order to develop
themselves to patient-centric, unanswered concerns in the regulatory end
might still result in a few companies to be reluctant. Despite having
guidance in place, it is not possible to make sure how the FDA is going
to impose its final judgment. The acceptance from the FDA during January
2015 associated with a number of mobile medical apps might give some
knowledge. In the decision, the FDA regarded the risk posed from the
system as “low to moderate.” It is likely to reduce concerns and
motivate the development of even more mobile apps. Even so, companies
must not move to the mHealth development services without having
complete knowledge what they really want from an app.
Powered by 10+ years of mobile healthcare expertise, Mindfire creates custom mHealth apps
for providers, patients & healthcare ISVs enabling exceptional
results in healthcare quality, effectiveness, and accessibility. If you
are in need of developing mHealth application software, mail your
requirements to sales at Mindfire Solutions dot com to let us help you
in your endeavor.